Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...
Investors poured into a room at #JPM26 to see how Revolution Medicines' CEO would dance around questions they knew he ...
The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...
US pharma major Merck (NYSE: MRK) has ended discussions to acquire Revolution Medicines (Nasdaq: RVMD) after the two sides failed to align on price, cooling a process that had briefly dangled a ...
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck ...
The company’s previous CCO was Cristal Downing, who joined Insulet as chief corporate affairs officer late last year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results